Bright Minds Biosciences Inc.(DRUG)Earnings, Financials & Key Ratios

DRUG•NASDAQ

Price updated Jun 19, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryNeuroscience and Psychiatry Therapies

AboutBright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.Show more

Revenue$0
EBITDA-$14M-404.1%
Net Income-$12M-336.5%
EPS (Diluted)-1.78-173.8%
ROE-27.93%+39.5%

DRUG Key Insights

Bright Minds Biosciences Inc. (DRUG) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Profits declining 91.1% over 5 years
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 59.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when DRUG posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

DRUG Price & Volume

Bright Minds Biosciences Inc. (DRUG) stock price & volume — 10-year historical chart

Loading chart...

DRUG Growth Metrics

Bright Minds Biosciences Inc. (DRUG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-699.23%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-336.01%

Return on Capital

10 Years-92.27%

5 Years-69.89%

3 Years-54.67%

Last Year-31.8%

DRUG Recent Earnings

Bright Minds Biosciences Inc. (DRUG) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (100%)

Q2 2026Latest

May 20, 2026

Metric

Actual

Est

EPS

$0.80+31.6%

$1.17

Rev

—

Q2 2026

May 19, 2026

Metric

Actual

Est

EPS

$0.80+12.7%

$0.92

Rev

—

Q1 2026

Feb 12, 2026

Metric

Actual

Est

EPS

$0.70+28.6%

$0.98

Rev

—

Q4 2025

Dec 23, 2025

Metric

Actual

Est

EPS

$0.41+27.1%

$0.56

Rev

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 20, 2026	$0.80vs $1.17+31.6%	—
Q2 2026	May 19, 2026	$0.80vs $0.92+12.7%	—
Q1 2026	Feb 12, 2026	$0.70vs $0.98+28.6%	—
Q4 2025	Dec 23, 2025	$0.41vs $0.56+27.1%	—

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
CMPSCOMPASS Pathways plcDirect Competitor	1.2B	12.53	-4.07			-151.02%
ATAIAtai Beckley N.VDirect Competitor	1.49B	4.06	-1.40	12.28%	-190.19%	-366.21%	0.01
MNMDMind Medicine (MindMed) Inc.Direct Competitor	2.04B	20.69	-10.04			-102.48%
CYBNCybin Inc.Direct Competitor	303.86M	6.09	-13.66			-81%
NRXPNRx Pharmaceuticals, Inc.Direct Competitor	68.62M	3.97	-2.96		-10.7%
ACADACADIA Pharmaceuticals Inc.Product Competitor	3.7B	21.62	9.44	11.87%	34.3%	35.65%	0.04
AXSMAxsome Therapeutics, Inc.Product Competitor	12.89B	250.50	-68.07	65.55%	-26.59%	-260.01%	2.73
INVAInnoviva, Inc.Product Competitor	1.66B	22.49	6.82	18.52%	118.91%	47.59%	0.23

Compare DRUG vs Peers

Bright Minds Biosciences Inc. (DRUG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CMPS

Most directly comparable listed peer for DRUG.

Scale Benchmark

vs LLY

Larger-name benchmark to compare DRUG against a more recognizable public peer.

Peer Set

Compare Top 5

vs CMPS, ATAI, MNMD, CYBN

DRUG Income Statement

Bright Minds Biosciences Inc. (DRUG) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Metric	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25	TTM
Sales/Revenue	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold	0	0	0	0	0	0	0	20.13K
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit	0▲ 0%	0▲ 0%	0▲ 0%	0▲ 0%	0▲ 0%	0▲ 0%	0▲ 0%	-20.13K▲ 0%
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-	-
Operating Expenses	236.15K	474.81K	8.62M	14.98M	7.39M	2.82M	13.94M	31.41M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	110.12K	114.51K	2.31M	2.55M	2.2M	1.45M	2.57M	4.72M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	126.03K	354.85K	6.31M	12.18M	5M	1.18M	11.08M	26.4M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	5.45K	0	243.08K	186.65K	197.19K	287.65K	290.67K
Operating Income	-236.15K▲ 0%	-474.93K▼ 101.1%	-8.62M▼ 1715.7%	-14.98M▼ 73.7%	-7.39M▲ 50.7%	-2.82M▲ 61.8%	-13.94M▼ 393.8%	-31.43M▲ 0%
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-101.11%	-1715.68%	-73.66%	50.68%	61.78%	-393.76%	-
EBITDA	0	0	0	-14.97M	-7.31M	-2.75M	-13.86M	-31.36M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-	51.14%	62.41%	-404.13%	-475.21%
D&A (Non-Cash Add-back)	236.15K	474.93K	8.62M	6.04K	72.45K	73.36K	76.87K	72.77K
EBIT	-236.15K	-474.93K	-8.62M	-14.98M	-7.39M	-2.82M	-13.94M	-31.43M
Net Interest Income	0	0	0	0	0	30.13K	1.52M	4.55M
Interest Income	0	0	0	0	0	30.13K	1.52M	4.56M
Interest Expense	0	0	0	0	0	0	0	5.59K
Other Income/Expense	0	-5.45K	-27.64K	10.15K	14.19K	20.82K	1.71M	3.91M
Pretax Income	-236.15K▲ 0%	-480.38K▼ 103.4%	-8.65M▼ 1700.8%	-14.96M▼ 73.0%	-7.37M▲ 50.7%	-2.8M▲ 62.0%	-12.23M▼ 336.5%	-27.53M▲ 0%
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax	0	0	0	0	0	0	0	0
Effective Tax Rate %	0%	0%	0%	0%	0%	0%	0%	0%
Net Income	-236.15K▲ 0%	-480.38K▼ 103.4%	-8.65M▼ 1700.8%	-14.96M▼ 73.0%	-7.37M▲ 50.7%	-2.8M▲ 62.0%	-12.23M▼ 336.5%	-27.53M▲ 0%
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-103.42%	-1700.83%	-72.99%	50.74%	61.99%	-336.46%	-699.23%
Net Income (Continuing)	-236.15K	-480.38K	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M	-27.53M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.06▲ 0%	-0.38▼ 517.9%	-4.74▼ 1147.4%	-6.15▼ 29.7%	-1.98▲ 67.8%	-0.65▲ 67.2%	-1.78▼ 173.8%	-2.87▲ 0%
EPS Growth %	-	-517.89%	-1147.37%	-29.75%	67.8%	67.17%	-173.85%	-336.01%
EPS (Basic)	-0.06	-0.38	-4.74	-6.15	-1.98	-0.65	-1.78	-
Diluted Shares Outstanding	1.28M	1.28M	1.79M	2.47M	3.72M	4.31M	6.88M	9.59M
Basic Shares Outstanding	1.28M	1.28M	1.79M	2.47M	3.72M	4.31M	6.88M	9.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

DRUG Balance Sheet

Bright Minds Biosciences Inc. (DRUG) balance sheet — assets, liabilities & shareholders' equity

Metric	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25	TTM
Total Current Assets	79.99K	878.22K	20.04M	11.95M	6.81M	5.99M	84.31M	312.07M
Cash & Short-Term Investments	79.99K	799.93K	19.76M	11.63M	6.75M	5.72M	82.91M	309.47M
Cash Only	79.99K	799.93K	19.76M	11.63M	6.75M	5.72M	82.91M	309.3M
Short-Term Investments	0	0	0	0	0	0	0	172.38K
Accounts Receivable	0	0	110.15K	155.78K	36.98K	50.22K	413.07K	1.14M
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	3
Total Non-Current Assets	83.98K	2K	2K	138.86K	66.41K	117.66K	111.97K	72.33K
Property, Plant & Equipment	0	0	0	138.86K	66.41K	117.66K	111.97K	72.33K
Fixed Asset Turnover	-	-	-	-	-	-	-	0.00x
Goodwill	0	2K	2K	0	0	0	0	0
Intangible Assets	2K	2	2	0	0	0	0	0
Long-Term Investments	81.98K	1K	33.68K	0	0	0	0	0
Other Non-Current Assets	0	-1K	-33.68K	0	0	0	0	0
Total Assets	163.97K▲ 0%	880.22K▲ 436.8%	20.04M▲ 2176.8%	12.09M▼ 39.7%	6.88M▼ 43.1%	6.1M▼ 11.3%	84.42M▲ 1282.9%	312.15M▲ 0%
Asset Turnover	-	-	-	-	-	-	-	0.00x
Asset Growth %	-	436.81%	2176.76%	-39.69%	-43.09%	-11.26%	1282.92%	2527.54%
Total Current Liabilities	36.71K	150.92K	638.57K	1.47M	280.86K	528.68K	2.34M	3.83M
Accounts Payable	36.71K	138.42K	596.57K	1.25M	182.31K	407.55K	1.71M	3.63M
Days Payables Outstanding	-	-	-	-	-	-	-	33.01K
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	-2.69K
Current Ratio	2.18x	5.82x	31.38x	8.11x	24.26x	11.32x	36.10x	81.48x
Quick Ratio	2.18x	5.82x	31.38x	8.11x	24.26x	11.32x	36.10x	81.48x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities	0	0	0	71.98K	0	39.58K	41.25K	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	71.98K	0	39.58K	41.25K	120.83K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	36.71K	150.92K	638.57K	1.54M	280.86K	568.26K	2.38M	3.83M
Total Debt	0	0	0	139.91K	73.55K	118.96K	125.78K	82.07K
Net Debt	-79.99K	-799.93K	-19.76M	-11.49M	-6.67M	-5.6M	-82.78M	-309.22M
Debt / Equity	-	-	-	0.01x	0.01x	0.02x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-0.00x
Net Debt / EBITDA	-	-	-	-	-	-	-	9.86x
Interest Coverage	-	-	-	-	-	-	-	-5621.26x
Total Equity	127.26K▲ 0%	729.29K▲ 473.1%	19.4M▲ 2560.4%	10.54M▼ 45.7%	6.6M▼ 37.4%	5.54M▼ 16.1%	82.04M▲ 1381.9%	308.32M▲ 0%
Equity Growth %	-	473.06%	2560.36%	-45.66%	-37.41%	-16.09%	1381.93%	2639.21%
Book Value per Share	0.10	0.57	10.81	4.27	1.77	1.28	11.93	32.15
Total Shareholders' Equity	127.26K	729.29K	19.4M	10.54M	6.6M	5.54M	82.04M	308.32M
Common Stock	205.98K	980.66K	27.08M	32.24M	33.91M	35.42M	123.25M	365.52M
Retained Earnings	-78.72K	-559.09K	-9.21M	-24.17M	-31.55M	-34.35M	-46.58M	-64.56M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-81.98K	161.3K	1.57M	2.48M	3.4M	4.01M	5.37M	7.35M
Minority Interest	0	0	0	0	0	0	0	0

DRUG Cash Flow Statement

Bright Minds Biosciences Inc. (DRUG) cash flow — operating, investing & free cash flow history

Metric	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25	TTM
Cash from Operations	-42.01K	-288.39K	-7.32M	-13.59M	-7.02M	-1.85M	-8.69M	-20.08M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-586.5%	-2437.97%	-85.63%	48.3%	73.66%	-369.77%	-2313.5%
Net Income	-78.72K	-480.38K	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M	-27.53M
Depreciation & Amortization	0	0	0	6.04K	72.45K	73.36K	76.87K	72.77K
Stock-Based Compensation	0	161.3K	880.62K	875.06K	1.15M	839.77K	3.18M	3.68M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	110.12K	161.3K	144.76K	-227.4K	65.1K	-1.18K	-276.84K	2.49M
Working Capital Changes	36.71K	30.68K	306.08K	724.13K	-941.72K	39.81K	554.99K	1.2M
Change in Receivables	0	0	-110.15K	-45.63K	118.8K	-13.24K	-362.85K	-889.97K
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0
Cash from Investing	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing	122K	1.01M	26.06M	5.2M	2.19M	810.57K	85.57M	279.19M
Debt Issued (Net)	0	0	0	-7.16K	-86.11K	-89.73K	-100.15K	-77.75K
Equity Issued (Net)	0	1.01M	27.74M	4.03M	1.22M	900.3K	86.03M	280.11M
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	366K	0	-1.69M	1.17M	1.06M	0	-360.14K	-839.67K
Net Change in Cash	79.99K▲ 0%	719.94K▲ 800.0%	18.96M▲ 2533.6%	-8.13M▼ 142.9%	-4.88M▲ 40.0%	-1.03M▲ 78.9%	77.19M▲ 7609.4%	252.25M▲ 0%
Free Cash Flow	-42.01K▲ 0%	-288.39K▼ 586.5%	-7.32M▼ 2438.0%	-13.59M▼ 85.6%	-7.02M▲ 48.3%	-1.85M▲ 73.7%	-8.69M▼ 369.8%	-20.08M▲ 0%
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-586.5%	-2437.97%	-85.63%	48.3%	73.66%	-369.77%	-384.81%
FCF per Share	-0.03	-0.23	-4.08	-5.50	-1.89	-0.43	-1.26	-2.09
FCF Conversion (FCF/Net Income)	0.18x	0.60x	0.85x	0.91x	0.95x	0.66x	0.71x	0.73x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

DRUG Key Ratios

Bright Minds Biosciences Inc. (DRUG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-112.16%	-85.94%	-99.95%	-86.02%	-46.18%	-27.93%	-20.72%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	13074.2%
Debt / Equity	-	-	0.01x	0.01x	0.02x	0.00x	0.00x
Interest Coverage	-	-	-	-	-	-	-5621.26x
FCF Conversion	0.60x	0.85x	0.91x	0.95x	0.66x	0.71x	0.73x

DRUG Frequently Asked Questions

Bright Minds Biosciences Inc. (DRUG) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Bright Minds Biosciences Inc. (DRUG) grew revenue by 0.0% over the past year. Growth has been modest.

Bright Minds Biosciences Inc. (DRUG) reported a net loss of $27.5M for fiscal year 2025.

Dividend & Returns

Bright Minds Biosciences Inc. (DRUG) has a return on equity (ROE) of -27.9%. Negative ROE indicates the company is unprofitable.

Bright Minds Biosciences Inc. (DRUG) had negative free cash flow of $20.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in DRUG back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

How much would $100/month in DRUG be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →

Bright Minds Biosciences Inc.(DRUG)Earnings, Financials & Key Ratios

DRUG•NASDAQ

Price updated Jun 19, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryNeuroscience and Psychiatry Therapies

Revenue$0
EBITDA-$14M-404.1%
Net Income-$12M-336.5%
EPS (Diluted)-1.78-173.8%
ROE-27.93%+39.5%